The team at ImmProNano is comprised of a group of scientists from diverse backgrounds bringing an inter-disciplinary expertise to service any immunological, proteomic and nanotechnological needs.
As scientists, we understand the value of properly gathered data and we strive to provide you with the highest quality service.
Mohan Philip, Ph.D., MBA
Dr. Philip is the President and a co-founder of ImmProNano. Dr. Philip is also the co-founder and COO of Immunotope, Inc., a company focused on therapeutic vaccines. Prior to Immunotope, he was Chief Scientific Officer of RHeoGene LLC a joint venture between Upstate and Rohm and Haas. Previously he has worked in research and development at Gencell (Sanofi) and Neurex (Elan). Dr. Philip helped founding of ABCRO, a clinical research organization and served on its board of directors till successful exit by acquisition. Dr. Philip received his Ph.D. from the Indian Institute of Science, Bangalore, India in Biological Sciences and did his postdoctoral work in Biochemistry Department at Stanford University.
Ramila Philip, Ph.D.
Dr. Philip is the Project Director and a co-founder of ImmProNano, as well as President and Chief Scientific Officer and chairman of the board of directors at Immunotope Inc. She also holds adjunct professor positions at the Drexel University, Department of Microbiology and Immunology and Blumberg Institute, a non-profit research institute of Hepatitis B Foundation. Dr. Philip developed immunoproteomics platform technologies and immunotherapy target discovery strategies at Immunotope. Her work included antigen discovery for ovarian, breast, prostate, lung and colon cancers and in infectious disease including HBV, HCV and Dengue viruses. Her discoveries lead to Phase I clinical trials in ovarian and breast cancer patients at Duke University.
Xiaofang Huang, Ph.D.
Dr. Huang is both a Project Manager in the Proteomic division and a co-founder of ImmProNano. Dr. Huang has over 10 years of experience in drug discovery and pre-clinical development with up-to-date knowledge and cutting-edge expertise in biomarker profiling, antigen discovery, omics analysis, analytical chemistry, pharmacokinetics and clinical pharmacology. As a co-founder of ImmProNano, Dr. Huang also works as a senior scientist and leads proteomic discovery at Immunotope Inc., a company focused on therapeutic vaccines. Prior to Immunotope, Dr. Huang received her Ph.D. from Temple University and her postdoc training at the proteomic core in Kimmel Cancer Center, Thomas Jefferson University. Before relocating in US, she was an analytical chemist in Waters Asia, where she provided extensive technical support in the field of HPLC and LCMSMS. Prior to joining Waters, she worked as a clinical pharmacist for three years and actively involved in several phase I clinical trials.
Project and Operations Manager
At ImmProNano, Mr. Karabudak is a Project & Operations Manager and a co-founder of ImmProNano. Aykan received his degree in Biomedical Engineering from Drexel University, and he has over seven years experience in the immunological, virology, oncology, and proteomic fields. His work includes therapeutic vaccine development via antigen discovery for ovarian, breast, prostate, lung and colon cancers and in infectious diseases including HBV, HCV and Dengue viruses. Prior to Immunotope, Mr. Karabudak had a variety of work experiences varying from NASA biomedical engineer to senior engineer and scientist for various research design projects.